You remember Goldman Sachs… they’re the multibillion dollar investment bank we taxpayers cured with a $10 billion injection during the financial crisis they helped cause. That was a teachable moment, but they apparently didn’t learn the lesson.
In a recent report to biotech investment clients, Goldman discussed the possibility that medical science may have gotten too successful for banking’s good. Asked whether “curing patients is a sustainable business model”, Goldman analysts came up with this horrifying answer…
“The potential to deliver “one shot cures” is one of the most attractive aspects of gene therapy, genetically engineered cell therapy, and gene editing. However, such treatments offer a very different outlook with regard to recurring revenue versus chronic therapies… While this proposition carries tremendous value for patients and society, it could represent a challenge for genome medicine developers looking for sustained cash flow.”
It gets worse… they explain how one 90%-effective cure has lowered their $12.5B revenue stream from chronic hepatitis patients to “just” $4B. Who can live on that?
“Ain’t no money in the cure, the money’s in the medicine… that’s how a drug dealer makes his money, on the comeback.” Click here to hear Chris Rock unload some more truth on you.
These articles will help you learn more, if you don’t develop chronic, incurable nausea from doing it. CNBC was the first to report, arsTechnica probably has the best story, but Lee Camp has the best, most irritated take on the whole thing…
“Is curing patients a sustainable business model?” Goldman Sachs analysts ask
Analyst report notes that Gilead’s hep C cure will make less than $4 billion this year. By Beth Mole on arsTechnica, Apr, 2018
Wall Street Admits Curing Diseases Is Bad For Business, by Lee Camp on PopularResistance.org, Apr 2018
Goldman Sachs asks in biotech research report: ‘Is curing patients a sustainable business model?’
by Tae Kim on CNBC, Apr 2018
